EULAR Highlights 2017
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Friday, June 16, <strong>2017</strong><br />
ORAL PRESENTATIONS<br />
From classics to new: synthetic DMARDs in RA<br />
Hall 7A – 10:15-11:45<br />
LB0003<br />
OP0230<br />
<br />
Tofacitinib With and Without Methotrexate Versus Adalimumab With<br />
Methotrexate for the Treatment of Rheumatoid Arthritis: Results From<br />
Oral Strategy, A Phase 3b/4 Randomised Trial<br />
The Effectiveness of Zoster Vaccine in RA Patients Subsequently Treated<br />
With Tofacitinib<br />
PsA: the options grow!<br />
Hall 8 – 10:15-11:45<br />
OP0216<br />
<br />
Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, or<br />
Adalimumab in Patients With Active Psoriatic Arthritis and an Inadequate<br />
Response to Conventional Synthetic Disease-Modifying Antirheumatic<br />
Drugs (csDMARDs): A Randomised, Placebo-Controlled, Phase 3 Trial<br />
Friday, June 16, <strong>2017</strong><br />
POSTERS<br />
FRI0071<br />
FRI0086<br />
Tofacitinib Restores the Inhibition of Reverse Cholesterol Transport<br />
Induced by Inflammation: Understanding the Lipid Paradox Associated<br />
With Rheumatoid Arthritis<br />
Efficacy and Safety Data Based on Historical or Pre-Existing Conditions<br />
at Baseline for Patients With Active Rheumatoid Arthritis Who Were<br />
Treated With Baricitinib<br />
FRI0087 Low Rates of Radiographic Progression of Structural Joint Damage Over 2<br />
Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis<br />
FRI0089 Effect of Starting Dose of Baricitinib In Achieving Sustained Low<br />
Disease Activity<br />
FRI0090 Analysis of Neutrophils, Lymphocytes, and Platelets In Pooled Phase 2<br />
and Phase 3 Studies of Baricitinib for Rheumatoid Arthritis<br />
FRI0092 Effects of Baricitinib on Haemoglobin and Related Laboratory<br />
Parameters in Rheumatoid Arthritis Patients<br />
FRI0096 Durability and Maintenance of Efficacy Following Prolonged Treatment<br />
With Baricitinib<br />
FRI0124 Temporary Interruptions of Study Drug During the Baricitinib Phase 3<br />
Rheumatoid Arthritis Program<br />
FRI0231 The First Report of Significant Increase of Body Mass Index in<br />
Rheumatoid Arthritis Patients Treated With Tofacitinib During 12-Month<br />
Follow-Up<br />
FRI0428 The JAK1-Selective Inhibitor, Filgotinib, Inhibits Inflammation Pathways<br />
Observed in an IL23-Induced Psoriatic Arthritis Mouse Model<br />
FRI0496 Comparing Tofacitinib Safety Profile in Patients With Psoriatic Arthritis in<br />
Clinical Studies With Real-World Data<br />
FRI0509 Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, Up To<br />
24 Months in Patients With Active Psoriatic Arthritis: Interim Data From<br />
Opal Balance, an Open-Label, Long-Term Extension Study<br />
Saturday, June 17, <strong>2017</strong><br />
POSTERS<br />
SAT0055<br />
SAT0058<br />
<br />
SAT0069<br />
SAT0070<br />
SAT0072<br />
<br />
SAT0149<br />
SAT0217<br />
SAT0439<br />
SAT0469<br />
SAT0686<br />
<br />
<strong>EULAR</strong> <strong>2017</strong><br />
Baricitinib Showed Rapid and Greater Reduction in Pain Compared to<br />
Adalimumab or Placebo in Patients With Rheumatoid Arthritis<br />
Effects of Baricitinib on Patients Who Stop Methotrexate Monotherapy<br />
and Switch to Baricitinib Monotherapy<br />
A Rapid3-Like Index Documents Superior Efficacy of Baricitinib to<br />
Adalimumab and Placebo, Similar To DAS28 And CDAI In The Ra-Beam<br />
Clinical Trial In Patients With Rheumatoid Arthritis<br />
Baricitinib Versus Adalimumab in Patients With Active Rheumatoid Arthritis:<br />
Analysis Of Patients Achieving a Moderate <strong>EULAR</strong> Response at Week 4<br />
Dose Reduction of Baricitinib in Patients With Rheumatoid Arthritis<br />
Achieving Sustained Disease Control: Results of a Prospective Study<br />
Comparative Effectiveness of Tofacitinib, Biologic Drugs and Traditional<br />
Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis<br />
Early Patient-Reported Outcomes and Clinical Outcomes With ABT-494<br />
in Patients With Active Rheumatoid Arthritis Who Are Inadequate<br />
Responders to Methotrexate or Tumor Necrosis Factor Inhibitors: Post-<br />
Hoc Analysis Of Phase 2 Randomized Controlled Trials<br />
Integrated Safety Summary of Tofacitinib in Psoriatic Arthritis Clinical Studies<br />
Integrated Efficacy Analysis of Tofacitinib, an Oral Janus Kinase Inhibitor,<br />
in Patients With Active Psoriatic Arthritis<br />
Major Adverse Cardiovascular Events: Risk Factors in Patients With RA<br />
Treated With Tofacitinib<br />
ABSTRACT ONLY<br />
AB0098 Effects of Tofacitinib in Early Arthritis Bone Loss<br />
AB0235 Effect of Baseline Disease Activity on Achieving Sustained Low Disease<br />
Activity in Baricitinib Phase 3 Studies<br />
AB0261 Clinical and Structural Responses of Patients With Active Rheumatoid<br />
Arthritis (RA) Using Step-Up Dosages of Tofacitinib In A Treat To<br />
Target Approach<br />
AB0281 Characterization of Changes In Lymphocyte Subsets in Baricitinib-<br />
Treated Patients With Early, DMARD Naïve, Rheumatoid Arthritis In A<br />
Phase 3 Study<br />
AB0403 Adherence and Access to Biological Therapy and Tofacitinib in a Cohort<br />
of Colombian Patients With Rheumatological Diseases<br />
AB0407 Comparative Effectiveness of Tocilizumab (TCZ) Monotherapy With<br />
Tumor Necrosis Factor Inhibitors (TNFi) in Combination With Varying<br />
Doses of Methotrexate (MTX) in Patients With Rheumatoid Arthritis<br />
AB0419 Real World Use of Tofacitinib in Rheumatoid Arthritis: Data From<br />
Latin America<br />
AB0431 Post-Marketing Surveillance of Tofacitinib in Japanese Patients With<br />
Rheumatoid Arthritis: An Interim Report Of Safety Data<br />
AB0432 ABT-494 Has No Effect on the QT Interval at the Doses Being Evaluated<br />
in Rheumatoid Arthritis Phase 3 Trials<br />
AB0434 Tofacitinib in Rheumatoid Arthritis: Real Life Experience<br />
AB0436 Comparison of Tofacitinib Efficacy in Patients With Moderate vs Severe<br />
Rheumatoid Arthritis: Pooled Analysis of Phase 3 Studies<br />
AB0794 Effect of Tofacitinib on Patient-Reported Outcomes in Patients With<br />
Active Psoriatic Arthritis: Results from Two Phase 3 Studies<br />
Chairman’s picks